Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
URGN 
UroGen Pharma Ltd (URGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: URGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.05% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 516.72M USD | Price to earnings Ratio - | 1Y Target Price 34.86 |
Price to earnings Ratio - | 1Y Target Price 34.86 | ||
Volume (30-day avg) 428734 | Beta 1.12 | 52 Weeks Range 9.03 - 20.70 | Updated Date 04/1/2025 |
52 Weeks Range 9.03 - 20.70 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-12 | When Before Market | Estimate -0.72 | Actual -0.8 |
Profitability
Profit Margin -140.35% | Operating Margin (TTM) -108.11% |
Management Effectiveness
Return on Assets (TTM) -25.78% | Return on Equity (TTM) -1481.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 396044589 | Price to Sales(TTM) 5.72 |
Enterprise Value 396044589 | Price to Sales(TTM) 5.72 | ||
Enterprise Value to Revenue 4.38 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 46094400 | Shares Floating 36992561 |
Shares Outstanding 46094400 | Shares Floating 36992561 | ||
Percent Insiders 8.4 | Percent Institutions 86.94 |
Analyst Ratings
Rating 4.67 | Target Price 39.93 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
UroGen Pharma Ltd
Company Overview
History and Background
UroGen Pharma Ltd. is a biopharmaceutical company founded in 2004. It focuses on developing and commercializing novel solutions to treat specialty cancers and urothelial diseases. Key milestones include the development and FDA approval of Jelmyto.
Core Business Areas
- Oncology: Develops and commercializes therapies for urothelial cancers, specifically upper tract urothelial carcinoma (UTUC) and bladder cancer.
Leadership and Structure
Liz Barrett is the President and CEO. The company has a typical biopharmaceutical organizational structure with departments focused on R&D, clinical development, commercial operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Jelmyto (mitomycin gel): Jelmyto is a retrograde intravesical instillation for the treatment of low-grade upper tract urothelial carcinoma (UTUC). Market share data is evolving, but it is the first and only non-surgical treatment option approved for this indication. Competitors include traditional surgical interventions like nephroureterectomy and ureteroscopic management.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation and regulatory approvals. There's a growing need for non-surgical cancer treatments.
Positioning
UroGen is positioned as a leader in uro-oncology, particularly in non-surgical treatments for UTUC. Its competitive advantage lies in its novel delivery system and first-to-market status with Jelmyto.
Total Addressable Market (TAM)
The estimated TAM for UTUC treatment is significant, with thousands of patients diagnosed annually. UroGen is positioned to capture a substantial share with Jelmyto, pending expansion into adjacent markets.
Upturn SWOT Analysis
Strengths
- First-to-market product (Jelmyto)
- Novel drug delivery technology
- Strong focus on uro-oncology
- Experienced management team
Weaknesses
- Reliance on a single product (Jelmyto)
- Limited commercial infrastructure
- High R&D expenses
- Dependence on reimbursement approvals
Opportunities
- Expansion of Jelmyto's label to include other indications
- Development of new products targeting urothelial diseases
- Partnerships with larger pharmaceutical companies
- Geographic expansion
Threats
- Competition from new therapies
- Failure to obtain or maintain regulatory approvals
- Unfavorable reimbursement policies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- MRK
Competitive Landscape
UroGen competes with larger pharmaceutical companies that offer traditional treatments for urothelial cancers. Its advantage lies in its non-surgical option for a specific patient population. However, these larger companies have significantly greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to Jelmyto's launch and market penetration.
Future Projections: Projections depend on Jelmyto sales growth, clinical trial outcomes, and new product development.
Recent Initiatives: Focus on expanding Jelmyto's market share and advancing its pipeline programs.
Summary
UroGen Pharma is a specialty pharmaceutical company with a unique product, Jelmyto, targeting a specific unmet need. Its success depends on expanding Jelmyto's market penetration and developing new products. The company faces competition from larger players and risks associated with regulatory approvals and reimbursement. While innovative, its long-term viability hinges on strategic execution and pipeline expansion.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About UroGen Pharma Ltd
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2017-05-04 | President, CEO & Director Ms. Elizabeth A. Barrett | ||
Sector Healthcare | Industry Biotechnology | Full time employees 235 | Website https://www.urogen.com |
Full time employees 235 | Website https://www.urogen.com | ||
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102, UGN-103 which is in phase 3 of clinical trial for intravesical solution, and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.